Vertex Pharmaceuticals Incorporated (VIE:VRTX)

Austria flag Austria · Delayed Price · Currency is EUR
370.00
+4.50 (1.23%)
At close: Oct 22, 2025
1.23%
Market Cap93.35B
Revenue (ttm)9.72B
Net Income (ttm)3.10B
Shares Outn/a
EPS (ttm)11.98
PE Ratio30.14
Forward PE21.65
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume25
Open367.35
Previous Close365.50
Day's Range367.35 - 370.00
52-Week Range313.80 - 487.50
Betan/a
RSI71.17
Earnings DateNov 3, 2025

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1989
Employees 6,100
Stock Exchange Vienna Stock Exchange
Ticker Symbol VRTX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.